S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
NASDAQ:BLTE

Belite Bio (BLTE) Stock Forecast, Price & News

$31.50
+2.30 (+7.88%)
(As of 09/22/2023 ET)
Compare
Today's Range
$29.37
$31.69
50-Day Range
$14.40
$36.64
52-Week Range
$11.00
$38.63
Volume
42,944 shs
Average Volume
91,168 shs
Market Capitalization
$857.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00

Belite Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
30.2% Upside
$41.00 Price Target
Short Interest
Healthy
0.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.01mentions of Belite Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.27) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

208th out of 965 stocks

Biotechnology Industry

2nd out of 15 stocks


BLTE stock logo

About Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

BLTE Price History

BLTE Stock News Headlines

Seven millionaires secretly enable market shock?
A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.
Belite Bio (NASDAQ: BLTE)
Expert Ratings for Belite Bio
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Belite Bio Incorporation American Depository Receipt Repr 1 Sh
The Latest Analyst Ratings for Belite Bio
Why Shares of Belite Bio Soared This Week
Analyst Expectations for Belite Bio's Future
Why Shares of Belite Bio Are Slumping Wednesday
See More Headlines
Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Company Calendar

Last Earnings
8/08/2023
Today
9/23/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLTE
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.00
High Stock Price Forecast
$57.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+30.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.67 per share

Miscellaneous

Free Float
23,610,000
Market Cap
$857.75 million
Optionable
Not Optionable
Beta
-2.10
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Yu-Hsin Lin M.B.A. (Age 44)
    Ph.D., Chairman of Directors & CEO
  • Mr. Hao-Yuan Chuang C.F.A. (Age 39)
    F.R.M., M.B.A., CFO & Director
  • Dr. Nathan L. Mata Ph.D. (Age 57)
    Chief Scientific Officer













BLTE Stock - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings
or view top-rated stocks.

What is Belite Bio's stock price forecast for 2023?

6 Wall Street research analysts have issued 1 year price targets for Belite Bio's stock. Their BLTE share price forecasts range from $25.00 to $57.00. On average, they anticipate the company's share price to reach $41.00 in the next year. This suggests a possible upside of 30.2% from the stock's current price.
View analysts price targets for BLTE
or view top-rated stocks among Wall Street analysts.

How have BLTE shares performed in 2023?

Belite Bio's stock was trading at $30.1450 at the beginning of the year. Since then, BLTE shares have increased by 4.5% and is now trading at $31.50.
View the best growth stocks for 2023 here
.

Are investors shorting Belite Bio?

Belite Bio saw a increase in short interest in August. As of August 31st, there was short interest totaling 37,500 shares, an increase of 7.1% from the August 15th total of 35,000 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is currently 0.5 days.
View Belite Bio's Short Interest
.

When is Belite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our BLTE earnings forecast
.

How were Belite Bio's earnings last quarter?

Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.03.

When did Belite Bio IPO?

(BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.

What is Belite Bio's stock symbol?

Belite Bio trades on the NASDAQ under the ticker symbol "BLTE."

Who are Belite Bio's major shareholders?

Belite Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atria Wealth Solutions Inc. (3.27%) and State Street Corp (0.05%).

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Belite Bio's stock price today?

One share of BLTE stock can currently be purchased for approximately $31.50.

How much money does Belite Bio make?

Belite Bio (NASDAQ:BLTE) has a market capitalization of $857.75 million.

How can I contact Belite Bio?

The official website for the company is belitebio.com. The company can be reached via phone at 858-246-6240 or via email at ir@belitebio.com.

This page (NASDAQ:BLTE) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -